# Xeljanz (tofacitinib citrate) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tofacitinib

> The FDA approved Xeljanz (tofacitinib citrate), sponsored by PFIZER INC (PFE), on September 25, 2020.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Xeljanz (tofacitinib citrate) |
| Codes |  |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### February 23, 2016: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA208246 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20160223, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ XR (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208246%22

### September 25, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213082 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20200925, review_priority PRIORITY; sponsor_name PFIZER; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213082%22

### September 25, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA203214 SUPPL-26 (Efficacy): submission_status AP, submission_status_date 20200925, review_priority PRIORITY; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22

### December 14, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA203214 SUPPL-28 (Efficacy): submission_status AP, submission_status_date 20211214, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22
- openFDA Drugs@FDA: "NDA208246 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20211214, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ XR (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208246%22

### February 21, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA203214 SUPPL-38 (Efficacy): submission_status AP, submission_status_date 20250221, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22
- openFDA Drugs@FDA: "NDA208246 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20250221, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ XR (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208246%22
- openFDA Drugs@FDA: "NDA213082 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250221, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213082%22

### October 16, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA203214 SUPPL-39 (Efficacy): submission_status AP, submission_status_date 20251016, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22
- openFDA Drugs@FDA: "NDA213082 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20251016, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213082%22

### March 6, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA203214 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22
- openFDA Drugs@FDA: "NDA208246 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ XR (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208246%22
- openFDA Drugs@FDA: "NDA213082 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name PFIZER; product XELJANZ (TOFACITINIB CITRATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213082%22

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT04624230

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04624230 (Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-17 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT04624230

## Same indication

- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tofacitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Xeljanz (tofacitinib citrate) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tofacitinib

```bibtex
@misc{secapidev_pdufa_tofacitinib_20261116,
  title        = {Xeljanz (tofacitinib citrate) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tofacitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tofacitinib_20261116","title":"Xeljanz (tofacitinib citrate) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tofacitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
